Liquid Biopsies Guide the Development of Cancer Drugs

Ashworth TR . A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. , 1869; 14: 146–147.

Leon SA , Shapiro B , Sklaroff DM , et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. , 1977; 37(3): 646–650.

Morgan TM . Liquid biopsy: Where did it come from, what is it, and where is it going?. Investig. Clin. Urol. , 2019; 60(3): 139–141. DOI: 10.4111/icu.2019.60.3.139.

Liu MC , MacKay M , Kase M , et al. Longitudinal shifts of solid tumor and liquid biopsy sequencing concordance in metastatic breast cancer. JCO Precis. Oncol. , 2022; 6(1): e2100321. DOI: 10.1200/PO.21.00321.

Porto V , Buceta D , Domínguez B , et al. Silver clusters of five atoms as highly selective antitumoral agents through irreversible oxidation of thiols. Adv. Funct. Mater . Published March 15, 2022. DOI: 10.1002/adfm.202113028.

Gritstone Bio. Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent. Published September 17, 2021. https://ir.gritstonebio.com/news-releases/ news-release-details/gritstone-announces-positive-clinical-data-granite.

Schenk D , Zhou R , Mantilla A , et al. Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients. Poster 4632. Presented at: American Association for Cancer Research Annual Meeting; April 8–13, 2022; New Orleans, LA.

Kura Oncology. Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer. Published April 8, 2022. https://ir.kuraoncology.com/news-releases/news-release-details/ kura-oncology-reports-preclinical-data-supporting-use-tipifarnib.

Forshew T , Murtaza M , Parkinson C , et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. , 2012; 4(136). DOI: 10.1126/scitranslmed.3003726.

Flach S , Howarth K , Hackinger S , et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—A personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br. J. Cancer , 2022; 126: 1186–1195. DOI: 10.1038/s41416-022-01716-7.